Scientists Solve a Sticky Problem
News Jan 08, 2014
Scientists have uncovered how an ulcer causing stomach bacteria, that has been linked to gastric cancer, sticks to and infects the lining of the stomach and gut.
Australian scientists have long had an interest in how the bacterium, Helicobacter pylori, causes ulcers and more rarely gastric cancer. Now, researchers led by Dr Terry Kwok and Professor James Whisstock, from Monash University’s Department of Biochemistry and Molecular Biology, have determined the 3-dimensional structure of a protein called SabA. SabA effectively acts as glue, sticking the bacteria to the lining the stomach, which can cause gastric disease.
Professor Whisstock said the findings could pave the way for potential new treatments for various gastric diseases.
“SabA is a type of protein known as an adhesin. As the name suggests, adhesins stick the bacteria to the cells lining the stomach. If we can stop SabA from working properly, then we may have a new approach for treating a range of different gastric diseases,” Professor Whisstock said.
The Monash University researchers pinpointed the part of SabA that is important for its stickiness, and they are now working to develop specific drugs that stop the protein from working properly.
Dr Kwok said infection with bacteria helicobacter pylori is the cause of most stomach and small intestine ulcers.
“Chronic Helicobacter pylori infection is an important problem, with re-occurring infections particularly difficult to treat, so there is great interest in developing new and specific drugs in this area,” Dr Kwok said.
The research was conducted at the Australian Synchrotron and recently published in the Journal of Biological Chemistry. The research was supported by the Australian Research Council and the National Health and Medical Research Council of Australia.
A team led by Professor Whisstock was granted $28 million last month from the Australian Research Council to establish the ARC Centre of Excellence in Advanced Molecular Imaging.
The centre will develop innovative imaging technologies to explore the immune system, leading to a better understanding of how the immune system functions.
New Opportunities for Type 2 Diabetes Drug Discovery: Researchers Determine Glucagon Receptor StructureNews
Complex structure of a class B GPCR bound to an analogue of its endogenous ligand ignites new excitement in GPCR research.READ MORE
Innovative ALS Therapy Startup Wins Golden Ticket Funding From AmgenNews
Amgen and LabCentral have announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral.READ MORE